Publication: Survival of stage III non-seminoma testis cancer patients versus simulated controls, according to race/ethnicity
Program
KU-Authors
KU Authors
Co-Authors
Morra, Simone
Cano Garcia, Cristina
Piccinelli, Mattia Luca
Tappero, Stefano
Barletta, Francesco
Incesu, Reha-Baris
Scheipner, Lukas
Baudo, Andrea
Tian, Zhe
de Angelis, Mario
Advisor
Publication Date
Language
en
Type
Journal Title
Journal ISSN
Volume Title
Abstract
Background It is unknown whether 5-year overall survival (OS) differs and to what extent between the American Joint Committee on Cancer stage III non-seminoma testicular germ cell tumor (NS-TGCT) patients and simulated age-matched male population-based controls, according to race/ethnicity groups. Methods We identified newly diagnosed (2004-2014) stage III NS-TGCT patients within the Surveillance Epidemiology and End Results database 2004-2019. For each case, we simulated an age-matched male control (Monte Carlo simulation), relying on Social Security Administration (SSA) Life Tables with 5 years of follow-up. We compared OS rates between stage III NS-TGCT patients and simulated age-matched male population-based controls, according to race/ethnicity groups (Caucasian, Hispanic, Asian/Pacific Islander and African American). Both, cancer-specific mortality (CSM) and other-cause mortality (OCM) were computed. Results Of 2054 stage III NS-TGCT patients, 60% were Caucasians versus 33% Hispanics versus 4% Asians/Pacific Islanders versus 3% African Americans. The 5-year OS difference between stage III NS-TGCT patients versus simulated age-matched male population-based controls was highest in Asians/Pacific Islanders (64 vs. 99%, Delta = 35%), followed by African Americans (66 vs. 97%, Delta = 31%), Hispanics (72 vs. 99%, Delta = 27%), and Caucasians (76 vs. 98%, Delta = 22%). The 5-year CSM rate was highest in Asians/Pacific Islanders (32%), followed by African Americans (26%), Hispanics (25%), and Caucasians (20%). The 5-year OCM rate was highest in African Americans (8%), followed by Caucasians (4%), Asians/Pacific Islanders (4%), and Hispanics (2%). Conclusion Relative to SSA Life Tables, the highest 5-year OS disadvantage applied to stage III NS-TGCT Asian/Pacific Islander race/ethnicity group, followed by African American, Hispanic and Caucasian, in that order.
Description
Source:
International Journal of Urology
Publisher:
Wiley
Keywords:
Subject
Urology and nephrology